Bionomics begins manufacture of anti-cancer stem cell treatment

04/25/2013 | Pharmaceutical Business Review Online

Bionomics has begun production work for BNC101, its stem cell therapy candidate for cancer, at its U.K. plant in Slough. "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials," said Bionomics' CEO and managing director, Deborah Rathjen. The firm expects clinical studies to start next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY